Together with GSK Oncology Enrollment Form

Fax completed enrollment form to 1-844-475-4662
For assistance, please call 1-844-4GSK-ONC
Monday-Friday (8 AM to 8 PM ET)

GSK
Together with GSK Oncology

Jemperli (dostarlimab-gxly) Injection 500 mg

Important Instructions:

Visit us at www.TogetherwithGSKOncology.com

Complete pages 2-4 of the Together with GSK Oncology Enrollment Form.

Patient to sign section 6 on page 3.
Healthcare professional to sign and date section 11 on page 4.
Fax the completed and signed enrollment form, plus copies of your patient's medical and pharmacy insurance cards, to 1-844-475-4662.

Patient Information (see pages 2 and 3)

Section 1: Select the services you are requesting.

Section 2: Complete the Patient Information.

Section 4 (optional – for eligible co-pay patients only): If you'd like to receive communications about your co-pay enrollment via telephone or text message, check the box to enroll.

Section 5 (optional): If you'd like to see if you're eligible for GSK's Patient Assistance Program (PAP), check the box to enroll, complete PAP information to research eligibility.

Section 6: Read HIPAA Patient Authorization on page 5, check the box, sign, and date.

Next steps: Together with GSK Oncology will call patients within 2 business days to provide coverage information for their prescribed treatment and offer co-pay assistance options for eligible patients.

Prescriber Information (see pages 2 and 4)

Section 3: Coverage for the product may be available under the medical or pharmacy benefit. Include legible copies (front and back) of the patient's medical and pharmacy insurance card(s). Include primary, secondary, Medicare/Medicaid (if eligible), and pharmacy benefit insurance information to ensure that ALL potential coverage options can be explored.

Section 7: Provide the Prescriber/Facility Information.

Section 8 (optional): Please include practice email if you would like the Together with GSK Oncology Co-pay Program to provide payment to the provider on behalf of eligible enrolled patients via EFT.

Section 9: Identify preferred shipping location if different than section 8.

Section 10: Clinical information is very important and often requested when verifying benefits. Diagnosis and appropriate ICD-10 code are required fields.

Section 11: Read Prescriber Declaration, sign, and date. A healthcare professional's signature is required.

Next steps: Together with GSK Oncology will confirm receipt by the next business day and conduct a summary of benefits call within 1-2 business days. Healthcare professionals will be notified regarding contact preferences and Together with GSK Oncology service options for patients.

Together with GSK Oncology Services:

- **Coverage Support**
  - Benefits Investigation
  - Prior Authorization Support
  - Appeals Support
  - Claims Assistance
- **Patient Assistance Program**
- **Commercial Co-pay Assistance**
- **Alternate Coverage Options**
  - Information About Patient Advocacy Organizations
  - Information About Independent Co-pay Foundations

GSK
Together with GSK Oncology

Jemperli (dostarlimab-gxly) Injection 500 mg

Visit us at www.TogetherwithGSKOncology.com

1 Check for Services Requested

❍ Coverage Support ❍ Patient Assistance Program ❍ Alternate Coverage Support
❍ Commercial Co-pay Assistance (review section 4 for texting options)

2 Patient Information

First Name: _____ Last Name: _____

Sex: ❍ Male ❍ Female Date of Birth: MM DD YYYY

Patient Address: _____ City: _____ State: _____ ZIP: _____

Home Phone #: _____ Cell Phone #: _____

Email: _____

Best Time to Contact: ❍ AM (8 AM to 10 AM) ❍ Day (10 AM to 5 PM) ❍ PM (after 5 PM)

Alt. Contact Name: _____

Alt. Contact Relationship to Patient: _____

Alt. Contact Phone #: _____

3 Insurance Information

Include a copy of both sides of the patient's insurance card(s).

Check Appropriate Box

❍ **Medicare** ❍ **Medicaid** ❍ **Commercial/Private** ❍ **Other** ❍ **Uninsured**

Primary Insurance Payer: _____

Insurance Name: _____

Phone #: _____

Policy ID #: _____ Group #: _____

BIN: _____ PCN: _____

Policy Holder Name: _____ Policy Holder Date of Birth: ____ / ____ / _____

Policy Holder Relationship to Patient: _____

Check Appropriate Box

❍ **Medicare** ❍ **Medicaid** ❍ **Commercial/Private** ❍ **Other** ❍ **Uninsured**

Secondary Insurance Payer: _____

Insurance Name: _____

Phone #: _____

Policy ID #: _____ Group #: _____

BIN: _____ PCN: _____

Policy Holder Name: _____ Policy Holder Date of Birth: ____ / ____ / _____

Policy Holder Relationship to Patient: _____

GSK
Together with GSK Oncology

Jemperli (dostarlimab-gxly) Injection 500 mg

Visit us at www.TogetherwithGSKOncology.com

Patient Name: _____ Date of Birth: ____ / ____ / _____

4 Texting Opt-in (Commercial Co-pay Assistance Only—Rates May Apply)

❍ By opting into texting for the Together with GSK Oncology Co-pay Program, you authorize GSK and its service provider to contact you and send communications about your co-pay enrollment via telephone and text message. These calls or text messages may be generated using auto-dial or pre-recorded messages at the number you submit. Message and data rates may apply. At any time, you may request to stop telephone calls or text messages by following the opt-out directions provided during those communications.

5 Patient Assistance Program (PAP) for Uninsured and Eligible Medicare Patients (Optional)

Uninsured and underinsured patients who are prescribed JEMPERLI may be eligible for GSK's Patient Assistance Program (PAP). (Please note that this does not constitute health insurance.) To find out if you qualify, please fill in the information below.

Medicare patients applying for PAP must provide their Medicare Beneficiary Identifier (MBI) found on their Medicare Health Insurance Card. It is 11 characters made up of letters and numbers (ex. 1EG4-TE5-MK73)

Patient MBI: _____

❍ **Enroll in PAP Program** **Annual pre-tax household income:** _____ **Number of family members living in household:** ____

Applicants authorize the Together with GSK Oncology PAP and its Administrators to obtain a consumer report. The consumer report, and the information derived from public and other sources, will be used to estimate income as part of the process to decide eligibility to receive free medication from GSK Oncology PAP. Upon request, GSK PAP will provide applicants with the name and address of the consumer reporting agency that provides the consumer report. The program may request additional documents and information at any time, even after enrollment, to determine if the information on the enrollment form is complete and true. For additional questions about eligibility, please contact Together with GSK Oncology.

6 REQUIRED: HIPAA Patient Authorization

Print Patient or Caregiver Name: _____ Relationship to Patient: _____

❍ I have read and agree to the **HIPAA Patient Authorization** included on page 5 **(required)**

PATIENT TO SIGN _____ PATIENT SIGNATURE HERE

For additional information regarding how GSK handles your information, please see our privacy statement at https://privacy.gsk.com/en-us/.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call **1-800-FDA-1088**.

GSK
Together with GSK Oncology

Jemperli (dostarlimab-gxly) Injection 500 mg

Visit us at www.TogetherwithGSKOncology.com

Patient Name: _____ Date of Birth: ____ / ____ / _____

7 Prescriber/Facility Information

Prescriber Name: _____ Prescriber Title: _____ Specialty: _____
NPI #: _____ DEA #: _____ Tax ID #: _____
Site/Facility Name: _____ NPI #: _____ Tax ID #: _____
Mailing Address: _____ City: _____ State: _____ ZIP: _____
Office Contact Name: _____ Office Contact Phone #: _____ Fax #: _____
Office Contact Email: _____

8 Co-pay Program Electronic Funds Transfer (EFT) Opt-in (Optional)

Please include practice email below if you would like the Together with GSK Oncology Co-pay Program to provide payment to the provider on behalf of eligible enrolled patients for patients' eligible co-pay via direct deposit. Disbursement of payment is subject to full provider enrollment in EFT and patient eligibility for the JEMPERLI Co-pay Program.

Practice Email Address: _____

9 Preferred Shipping Location

Facility Name: _____ Phone #: _____
Street: _____ City: _____ State: _____ ZIP: _____
Site of Administration: ❍ Physician's office ❍ Hospital outpatient ❍ Another site of care

10 Clinical Information

Diagnosis ICD-10 Code	❍ C54.1-Malignant neoplasm of endometrium	❍ Other: _____

Mismatch repair status (MMR):
❍ Mismatch repair deficient (dMMR)
❍ Mismatch repair proficient (MMRp)

Endometrial cancer prior therapies: (check all that apply)
❍ Treatment with platinum-containing regimen
❍ Other: _____

PRESCRIPTION:

MEDICATION	STRENGTH/FORM	DIRECTIONS FOR ADMINISTRATION
❍ JEMPERLI IV	Injection: clear to slightly opalescent, colorless to yellow solution supplied in a carton containing one 500 mg/10 mL (50 mg/mL), single-dose vial (NDC 0173-0898-03)	• Dose 1 through 4: 500 mg every 3 weeks. • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg every 6 weeks. • Administer as an intravenous infusion over 30 minutes.

11 REQUIRED: Prescriber Declaration

I certify that the information provided above is true and that JEMPERLI is being prescribed for the patient listed above. I hereby certify that, for any insured patient seeking co-pay assistance under the Co-pay Program, in the absence of financial support from such program, any applicable co-pay, coinsurance, or other out-of-pocket cost for JEMPERLI would be collected from the patient upon treatment. I appoint Together with GSK Oncology, on my behalf, to convey this prescription to the dispensing pharmacy, to the extent permitted under state law. Special Note: Prescribers in all states must follow applicable laws for a valid prescription. For prescribers in states with official prescription form requirements, please submit an actual prescription along with this enrollment form. Prescribers may need to submit an electronic prescription to the specialty pharmacy.

HEALTHCARE PROFESSIONAL TO SIGN _____ NO STAMPS PLEASE Date: ____ / ____ / _____

GSK
Together with GSK Oncology

Jemperli (dostarlimab-gxly) Injection 500 mg

Visit us at www.TogetherwithGSKOncology.com

REQUIRED: HIPAA Patient Authorization

By signing this form on page 3, **I agree** to allow my doctors, pharmacies, including my specialty pharmacy(ies), and health insurers (collectively "Healthcare Providers"), to use and disclose my health information to GSK and its agents, authorized representatives, and contractors (collectively "GSK") so that GSK can use and disclose my health information for purposes of providing Together with GSK Oncology services, which may include the following activities:

1. Communicating with my Healthcare Providers about my BLENREP prescription and medical condition;
2. Providing ophthalmology support, including ophthalmologist referral information and appointment reminders;
3. Investigating and resolving my insurance coverage, coding, or reimbursement inquiry, or reviewing my eligibility for GSK's patient assistance and co-pay assistance programs;
4. Contacting my insurer, other potential funding sources, and/or patient assistance programs on my behalf to determine if I am eligible for health insurance coverage or other funds;
5. Disclosing my information to third parties if required by law.

By signing this authorization, **I acknowledge** my understanding that:

- My Healthcare Providers will not and may not condition my treatment, payment for treatment, or eligibility for or enrollment in benefits on whether I sign this patient authorization.
- Certain Healthcare Providers, such as specialty pharmacies, may receive payment from GSK for disclosing my information to GSK as permitted by this authorization.
- Once information about me is released to GSK based on this authorization, federal privacy laws may no longer protect my information and may not prevent GSK from further disclosing my information. However, I understand that GSK has agreed to use or disclose information received only for the purposes described in this authorization or as required by law.
- This authorization will remain in effect for two (2) years after I sign it (unless a shorter period is required by state law) or for as long as I participate in the Together with GSK Oncology program, whichever is longer.
- I have the right to revoke this authorization at any time by mailing a signed written statement of my revocation to **Together with GSK Oncology, P.O. Box 5490, Louisville, KY 40255**, but such a revocation would end my eligibility to participate in the Together with GSK Oncology program. Revoking this authorization will prohibit further disclosures by my Healthcare Providers based on this authorization after the date a written revocation is received, but will not apply to the extent that they have already taken action in reliance on this authorization. After this authorization is revoked, I understand that information provided to GSK prior to the revocation may be disclosed within GSK to maintain records of my participation.

The patient, or the patient's authorized representative,* MUST *sign this form (section 6) in order for the patient to receive Together with GSK Oncology services. If an authorized representative signs for the patient, please indicate relationship to the patient.

GSK

DSTBROC220010 September 2022
Produced in USA. 0002-0020-20